ClinicalTrials.gg
CompletedNCT01063517Updated Jul 20, 2023Results posted

Efficacy Study of Olaparib With Paclitaxel Versus Paclitaxel in Gastric Cancer Patients

A Phase 2 interventional study of olaparib and paclitaxel in Gastric Cancer, sponsored by AstraZeneca. Completed at 7 sites in Korea, Republic of. Open to participants aged 18 Years to 130 Years. Per ClinicalTrials.gov, last updated 2023-07-20.

Sponsored by AstraZeneca · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
124
Allocation
Randomized
Ages
18 Years to 130 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 30 studies in Stomach Neoplasms by AstraZeneca — 10 open to participants now, 18 under way, 3 of them phase 3. Stomach Neoplasms · AstraZeneca.

Enrollment
14th of 27
124 · median 124
Started
2010
with 1 other
Phase 2
9 of 30
4 open now
Registered
3rd of 30
by date

Among the 30 studies in Stomach Neoplasms by AstraZeneca, this one is the 14th largest by enrollment of the 27 interventional ones that give a count, is one of 2 that started in 2010, is one of 9 in phase 2, and was the 3rd registered.

Stomach Neoplasms

3,403 studies on the registry are indexed under Stomach Neoplasms; 995 are open to participants now.

Browse Stomach Neoplasms studies →

Open to participants now

10 of the 30 studies in Stomach Neoplasms by AstraZeneca are open now, in 12 countries. Recruiting first, the newest first:

5 more — sign in →

By country, each count listing its studies:

All 10 open studies →

Who these studies take

Of the 704 Stomach Neoplasms studies recruiting now, 376 (53%) set no upper age limit and 194 (28%) stop at 75 or younger; 28 take children under 18; 69 take healthy volunteers.

This study: 18 Years to 130 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 30 studies in Stomach Neoplasms by AstraZeneca, or all of them as a file.
02

Study summary

To assess the efficacy of olaparib when given in combination with paclitaxel compared with paclitaxel alone as defined by progression-free survival (PFS), in all patients with recurrent and metastatic gastric cancer who progress following first-line therapy.

03

Conditions studied

  • Gastric Cancer

Browse trials for

Keywords

  • Poly(ADP ribose)
  • polymerase (PARP)
  • Gastric cancer
  • olaparib
  • PARP inhibitor
  • ATM AZD2281
  • Ku0059436
  • Homologous Recombination deficiency (HRD)
  • Recurrent gastric cancer
  • metastatic gastric cancer
04

Who can participate

Ages eligible
18 Years to 130 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Recurrent or gastric cancer that has progressed following -therapy
  • Confirmed ATM protein status by IHC
  • At least one lesion (measurable and/or non-measurable) that can be accurately assessed by imaging (CT/MRI) at baseline and follow up visits

Exclusion criteria

Exclusion Criteria:

  • More than one prior chemotherapy regimen for the treatment of gastric cancer in the or recurrent setting
  • Any previous treatment with a PARP inhibitor, including olaparib
  • Patients with second primary cancer, except; adequately treated non melanoma skin cancer, curatively treated in situ cancer of the cervix, or other solid tumours curatively treated with no evidence of disease for >5 years
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
124 participants (actual)

Study arms

  • Experimental
    1

    Olaparib + paclitaxel

    Drug: olaparib · Drug: paclitaxel

  • Active comparator
    2

    paclitaxel + placebo

    Drug: paclitaxel · Drug: Placebo

Interventions

  • 100mg BID oral tablet continuous

  • iv infusion 80mg/m2 on Day 1, 8 and 15 of a 28 day cycle

    Also known as: Taxol

  • DrugPlacebo

    100mg BID oral tablet to match olaparib tablet

06

What researchers measure

Primary outcomes

  1. Progression Free Survival (PFS) in the Overall Study Population

    PFS is defined as the time from randomisation till objective progression or death. In absence of progression or death, the time is calculated from randomisation till last evaluable scanning visit.

    Time frame: Tumour assessments were carried out at baseline and then follow up assessments taken every 8 weeks up to Week 40 and then every 16 weeks until objective disease progression as defined by RECIST 1.1, assessed maximum up to 27 months

  2. Progression Free Survival (PFS) in Patients With Tumours Defined as Homologous Recombination Deficient by Loss of Ataxia-Telangiectasia Mutation (ATM) Protein [ATM Negative Patients]

    PFS is defined as the time from randomisation till objective progression or death. In absence of progression or death, the time is calculated from randomisation till last evaluable scanning visit.

    Time frame: Tumour assessments are carried out at baseline and then follow up assessments taken every 8 weeks up to Week 40 and then every 16 weeks until objective disease progression as defined by RECIST 1.1, assessed maximum up to 27 months

Secondary outcomes

  1. Overall Survival (OS) in the Overall Study Population

    Overall survival is defined as the duration from randomisation till death. In absence of death, the time is calculated from randomisation till the date subject last known to be alive.

    Time frame: Survival follow up from randomisation till death of the patient or till end of study in absence of death, assessed maximum up to 27 months

  2. Overall Survival (OS) in ATM Negative Patients

    Overall survival is defined as the duration from randomisation till death. In absence of death, the time is calculated from randomisation till the date subject last known to be alive.

    Time frame: Survival follow up from randomisation till death of the patient or till end of study in absence of death, assessed maximum up to 27 months

  3. Objective Response Rate (ORR) in the Overall Study Population

    Objective response rate is the proportion of patients with at least one measurable lesion at baseline, who experienced complete or partial response at least once during the assessment period, according to the definitions of Response Evaluation Criteria In Solid Tumours (RECIST version 1.1).

    Time frame: Tumour assessments carried out at baseline, 28 days before randomisation then every 8 weeks until week 40, after week 40 assessments will be carried out every 16 weeks until objective disease progression, assessed maximum up to 27 months

  4. Objective Response Rate (ORR) in the ATM Negative Patients

    Objective response rate is the proportion of ATM negative patients with at least one measurable lesion at baseline, who experienced complete or partial response at least once during the assessment period, according to the definitions of Response Evaluation Criteria In Solid Tumours (RECIST version 1.1).

    Time frame: Tumour assessments carried out at baseline, 28 days before randomisation then every 8 weeks until week 40, after week 40 assessments will be carried out every 16 weeks until objective disease progression, assessed maximum up to 27 months

  5. Percentage Change in Tumour Size at Week 8 in the Overall Study Population

    Percentage change in tumour size from baseline to Week 8 calculated as 100 X (week 8 tumour size - baseline tumour size) / (baseline tumour size)

    Time frame: Tumour scans done at Baseline and week 8

  6. Percentage Change in Tumour Size at Week 8 in the ATM Negative Patients

    Percentage change in tumour size from baseline to Week 8 calculated as 100 X (week 8 tumour size - baseline tumour size) / (baseline tumour size)

    Time frame: Tumour scans done at Baseline and week 8

  7. Time to Deterioration in Global Quality of Life (QoL) Score in the Overall Study Population

    Time calculated from randomisation till worsening of Global QoL score based on European Organisation for Research and Treatment of Cancer (EORTC) questionnaire data

    Time frame: Questionnaire data collected at Baseline ie on or before date of randomisation, every 4 weeks post baseline, assessed maximum up to 27 months

  8. Time to Deterioration in QoL Fatigue Score in the Overall Study Population

    Time calculated from randomisation till worsening of fatigue score based on European Organisation for Research and Treatment of Cancer (EORTC) questionnaire data

    Time frame: Questionnaire data collected at Baseline ie on or before date of randomisation, every 4 weeks post baseline, assessed maximum up to 27 months

  9. Time to Deterioration in QoL Nausea & Vomiting Domain Score in the Overall Study Population

    Time calculated from randomisation till worsening of nausea \& vomiting domain score based on European Organisation for Research and Treatment of Cancer (EORTC) questionnaire data

    Time frame: Questionnaire data collected at Baseline ie on or before date of randomisation, every 4 weeks post baseline, assessed maximum up to 27 months

  10. Time to Deterioration in QoL Pain Domain Score in the Overall Study Population

    Time calculated from randomisation till worsening of pain domain score based on European Organisation for Research and Treatment of Cancer (EORTC) questionnaire data

    Time frame: Questionnaire data collected at Baseline ie on or before date of randomisation, every 4 weeks post baseline, assessed maximum up to 27 months

  11. Time to Deterioration in QoL Dysphagia Domain Score in the Overall Study Population

    Time calculated from randomisation till worsening of dysphagia domain score based on European Organisation for Research and Treatment of Cancer (EORTC) questionnaire data

    Time frame: Questionnaire data collected at Baseline ie on or before date of randomisation, every 4 weeks post baseline, assessed maximum up to 27 months

  12. Time to Deterioration in QoL Eating Restriction Domain Score in the Overall Study Population

    Time calculated from randomisation till worsening of eating restriction domain score based on European Organisation for Research and Treatment of Cancer (EORTC) questionnaire data

    Time frame: Questionnaire data collected at Baseline ie on or before date of randomisation, every 4 weeks post baseline, assessed maximum up to 27 months

  13. Time to Deterioration in QoL Stomach Pain Domain Score in the Overall Study Population

    Time calculated from randomisation till worsening of stomach pain domain score based on European Organisation for Research and Treatment of Cancer (EORTC) questionnaire data

    Time frame: Questionnaire data collected at Baseline ie on or before date of randomisation, every 4 weeks post baseline, assessed maximum up to 27 months

  14. Time to Deterioration in QoL Reflux Domain Score in the Overall Study Population

    Time calculated from randomisation till worsening of reflux domain score based on European Organisation for Research and Treatment of Cancer (EORTC) questionnaire data

    Time frame: Questionnaire data collected at Baseline ie on or before date of randomisation, every 4 weeks post baseline, assessed maximum up to 27 months

  15. Time to Deterioration in QoL Anxiety Domain Score in the Overall Study Population

    Time calculated from randomisation till worsening of anxiety domain score based on European Organisation for Research and Treatment of Cancer (EORTC) questionnaire data

    Time frame: Questionnaire data collected at Baseline ie on or before date of randomisation, every 4 weeks post baseline, assessed maximum up to 27 months

07

Results

Posted Apr 30, 2015

Participant flow

This study was conducted at 13 sites in South Korea. Enrolment started in February 2010 and was completed in May 2012. In total 124 patients were randomised in the study (62 in the olaparib+paclitaxel arm and 62 in the placebo+paclitaxel arm).

Participant flow — Overall Study
MilestoneOlaparib+PaclitaxelPlacebo+Paclitaxel
Started6262
Received randomised treatment6162
Completed42
Not completed5860
Withdrew: Consent withdrawal10
Withdrew: Study reached data cut-off197
Withdrew: Lost to follow-up43
Withdrew: Withdrawal by subject12
Withdrew: Death3348

Outcome measures

PrimaryProgression Free Survival (PFS) in the Overall Study Population

PFS is defined as the time from randomisation till objective progression or death. In absence of progression or death, the time is calculated from randomisation till last evaluable scanning visit.

Time frame:
Tumour assessments were carried out at baseline and then follow up assessments taken every 8 weeks up to Week 40 and then every 16 weeks until objective disease progression as defined by RECIST 1.1, assessed maximum up to 27 months
Reported as:
Median · months
Progression Free Survival (PFS) in the Overall Study Population
monthsOlaparib+PaclitaxelPlacebo+Paclitaxel
Progression Free Survival (PFS) in the Overall Study Population3.91 (3.02 to 7.13)3.55 (1.74 to 5.82)
Statistical analysis
  • Olaparib+Paclitaxel vs Placebo+Paclitaxel · Hazard ratio (hr): 0.8 · 80% CI 0.62 to 1.03The numerator of the hazard ratio is hazards of progression in olaparib+paclitaxel group and denominator is hazards of progression in placebo+paclitaxel group. Confidence intervals are calculated using the profile-likelihood method.
PrimaryProgression Free Survival (PFS) in Patients With Tumours Defined as Homologous Recombination Deficient by Loss of Ataxia-Telangiectasia Mutation (ATM) Protein [ATM Negative Patients]

PFS is defined as the time from randomisation till objective progression or death. In absence of progression or death, the time is calculated from randomisation till last evaluable scanning visit.

Time frame:
Tumour assessments are carried out at baseline and then follow up assessments taken every 8 weeks up to Week 40 and then every 16 weeks until objective disease progression as defined by RECIST 1.1, assessed maximum up to 27 months
Reported as:
Median · months
Progression Free Survival (PFS) in Patients With Tumours Defined as Homologous Recombination Deficient by Loss of Ataxia-Telangiectasia Mutation (ATM) Protein [ATM Negative Patients]
monthsOlaparib+PaclitaxelPlacebo+Paclitaxel
Progression Free Survival (PFS) in Patients With Tumours Defined as Homologous Recombination Deficient by Loss of Ataxia-Telangiectasia Mutation (ATM) Protein [ATM Negative Patients]5.29 (3.38 to 5.72)3.68 (1.77 to 5.82)
Statistical analysis
  • Olaparib+Paclitaxel vs Placebo+Paclitaxel · Hazard ratio (hr): 0.74 · 80% CI 0.51 to 1.08The numerator of the hazard ratio is hazards of progression in olaparib+paclitaxel group and denominator is hazards of progression in placebo+paclitaxel group. Confidence intervals are calculated using the profile-likelihood method.
SecondaryOverall Survival (OS) in the Overall Study Population

Overall survival is defined as the duration from randomisation till death. In absence of death, the time is calculated from randomisation till the date subject last known to be alive.

Time frame:
Survival follow up from randomisation till death of the patient or till end of study in absence of death, assessed maximum up to 27 months
Reported as:
Median · months
Overall Survival (OS) in the Overall Study Population
monthsOlaparib+PaclitaxelPlacebo+Paclitaxel
Overall Survival (OS) in the Overall Study Population13.1 (7.10 to NA)8.3 (5.30 to 14.90)
Statistical analysis
  • Olaparib+Paclitaxel vs Placebo+Paclitaxel · Hazard ratio (hr): 0.56 · 80% CI 0.41 to 0.75The numerator of the hazard ratio is hazards of death in olaparib+paclitaxel group and denominator is hazards of death in placebo+paclitaxel group. Confidence intervals are calculated using the profile-likelihood method.
SecondaryOverall Survival (OS) in ATM Negative Patients

Overall survival is defined as the duration from randomisation till death. In absence of death, the time is calculated from randomisation till the date subject last known to be alive.

Time frame:
Survival follow up from randomisation till death of the patient or till end of study in absence of death, assessed maximum up to 27 months
Reported as:
Median · months
Overall Survival (OS) in ATM Negative Patients
monthsOlaparib+PaclitaxelPlacebo+Paclitaxel
Overall Survival (OS) in ATM Negative PatientsNA (9.30 to NA)8.20 (5.10 to 13.10)
Statistical analysis
  • Olaparib+Paclitaxel vs Placebo+Paclitaxel · Hazard ratio (hr): 0.35 · 80% CI 0.22 to 0.56The numerator of the hazard ratio is hazards of death in olaparib+paclitaxel group and denominator is hazards of death in placebo+paclitaxel group. Confidence intervals are calculated using the profile-likelihood method.
SecondaryObjective Response Rate (ORR) in the Overall Study Population

Objective response rate is the proportion of patients with at least one measurable lesion at baseline, who experienced complete or partial response at least once during the assessment period, according to the definitions of Response Evaluation Criteria In Solid Tumours (RECIST version 1.1).

Time frame:
Tumour assessments carried out at baseline, 28 days before randomisation then every 8 weeks until week 40, after week 40 assessments will be carried out every 16 weeks until objective disease progression, assessed maximum up to 27 months
Reported as:
Number · Participants
Objective Response Rate (ORR) in the Overall Study Population
ParticipantsOlaparib+PaclitaxelPlacebo+Paclitaxel
Objective Response Rate (ORR) in the Overall Study Population149
SecondaryObjective Response Rate (ORR) in the ATM Negative Patients

Objective response rate is the proportion of ATM negative patients with at least one measurable lesion at baseline, who experienced complete or partial response at least once during the assessment period, according to the definitions of Response Evaluation Criteria In Solid Tumours (RECIST version 1.1).

Time frame:
Tumour assessments carried out at baseline, 28 days before randomisation then every 8 weeks until week 40, after week 40 assessments will be carried out every 16 weeks until objective disease progression, assessed maximum up to 27 months
Reported as:
Number · Participants
Objective Response Rate (ORR) in the ATM Negative Patients
ParticipantsOlaparib+PaclitaxelPlacebo+Paclitaxel
Objective Response Rate (ORR) in the ATM Negative Patients96
SecondaryPercentage Change in Tumour Size at Week 8 in the Overall Study Population

Percentage change in tumour size from baseline to Week 8 calculated as 100 X (week 8 tumour size - baseline tumour size) / (baseline tumour size)

Time frame:
Tumour scans done at Baseline and week 8
Reported as:
Mean · Percent change
Percentage Change in Tumour Size at Week 8 in the Overall Study Population
Percent changeOlaparib+PaclitaxelPlacebo+Paclitaxel
Percentage Change in Tumour Size at Week 8 in the Overall Study Population-5.8 ± 29.092.2 ± 35.6
SecondaryPercentage Change in Tumour Size at Week 8 in the ATM Negative Patients

Percentage change in tumour size from baseline to Week 8 calculated as 100 X (week 8 tumour size - baseline tumour size) / (baseline tumour size)

Time frame:
Tumour scans done at Baseline and week 8
Reported as:
Mean · Percent change
Percentage Change in Tumour Size at Week 8 in the ATM Negative Patients
Percent changeOlaparib+PaclitaxelPlacebo+Paclitaxel
Percentage Change in Tumour Size at Week 8 in the ATM Negative Patients-6.9 ± 29.31-5.9 ± 26.36
SecondaryTime to Deterioration in Global Quality of Life (QoL) Score in the Overall Study Population

Time calculated from randomisation till worsening of Global QoL score based on European Organisation for Research and Treatment of Cancer (EORTC) questionnaire data

Time frame:
Questionnaire data collected at Baseline ie on or before date of randomisation, every 4 weeks post baseline, assessed maximum up to 27 months
Reported as:
Median · months
Time to Deterioration in Global Quality of Life (QoL) Score in the Overall Study Population
monthsOlaparib+PaclitaxelPlacebo+Paclitaxel
Time to Deterioration in Global Quality of Life (QoL) Score in the Overall Study Population3.6 ± 29.312.8 ± 26.36
SecondaryTime to Deterioration in QoL Fatigue Score in the Overall Study Population

Time calculated from randomisation till worsening of fatigue score based on European Organisation for Research and Treatment of Cancer (EORTC) questionnaire data

Time frame:
Questionnaire data collected at Baseline ie on or before date of randomisation, every 4 weeks post baseline, assessed maximum up to 27 months
Reported as:
Median · months
Time to Deterioration in QoL Fatigue Score in the Overall Study Population
monthsOlaparib+PaclitaxelPlacebo+Paclitaxel
Time to Deterioration in QoL Fatigue Score in the Overall Study Population1.9 ± 29.311.8 ± 26.36
SecondaryTime to Deterioration in QoL Nausea & Vomiting Domain Score in the Overall Study Population

Time calculated from randomisation till worsening of nausea \& vomiting domain score based on European Organisation for Research and Treatment of Cancer (EORTC) questionnaire data

Time frame:
Questionnaire data collected at Baseline ie on or before date of randomisation, every 4 weeks post baseline, assessed maximum up to 27 months
Reported as:
Median · months
Time to Deterioration in QoL Nausea & Vomiting Domain Score in the Overall Study Population
monthsOlaparib+PaclitaxelPlacebo+Paclitaxel
Time to Deterioration in QoL Nausea & Vomiting Domain Score in the Overall Study Population3.7 ± 29.313.7 ± 26.36
SecondaryTime to Deterioration in QoL Pain Domain Score in the Overall Study Population

Time calculated from randomisation till worsening of pain domain score based on European Organisation for Research and Treatment of Cancer (EORTC) questionnaire data

Time frame:
Questionnaire data collected at Baseline ie on or before date of randomisation, every 4 weeks post baseline, assessed maximum up to 27 months
Reported as:
Median · months
Time to Deterioration in QoL Pain Domain Score in the Overall Study Population
monthsOlaparib+PaclitaxelPlacebo+Paclitaxel
Time to Deterioration in QoL Pain Domain Score in the Overall Study Population3.2 ± 29.313.1 ± 26.36
SecondaryTime to Deterioration in QoL Dysphagia Domain Score in the Overall Study Population

Time calculated from randomisation till worsening of dysphagia domain score based on European Organisation for Research and Treatment of Cancer (EORTC) questionnaire data

Time frame:
Questionnaire data collected at Baseline ie on or before date of randomisation, every 4 weeks post baseline, assessed maximum up to 27 months
Reported as:
Median · months
Time to Deterioration in QoL Dysphagia Domain Score in the Overall Study Population
monthsOlaparib+PaclitaxelPlacebo+Paclitaxel
Time to Deterioration in QoL Dysphagia Domain Score in the Overall Study Population3.7 ± 29.311.9 ± 26.36
SecondaryTime to Deterioration in QoL Eating Restriction Domain Score in the Overall Study Population

Time calculated from randomisation till worsening of eating restriction domain score based on European Organisation for Research and Treatment of Cancer (EORTC) questionnaire data

Time frame:
Questionnaire data collected at Baseline ie on or before date of randomisation, every 4 weeks post baseline, assessed maximum up to 27 months
Reported as:
Median · months
Time to Deterioration in QoL Eating Restriction Domain Score in the Overall Study Population
monthsOlaparib+PaclitaxelPlacebo+Paclitaxel
Time to Deterioration in QoL Eating Restriction Domain Score in the Overall Study Population4.6 ± 29.315.1 ± 26.36
SecondaryTime to Deterioration in QoL Stomach Pain Domain Score in the Overall Study Population

Time calculated from randomisation till worsening of stomach pain domain score based on European Organisation for Research and Treatment of Cancer (EORTC) questionnaire data

Time frame:
Questionnaire data collected at Baseline ie on or before date of randomisation, every 4 weeks post baseline, assessed maximum up to 27 months
Reported as:
Median · months
Time to Deterioration in QoL Stomach Pain Domain Score in the Overall Study Population
monthsOlaparib+PaclitaxelPlacebo+Paclitaxel
Time to Deterioration in QoL Stomach Pain Domain Score in the Overall Study Population6.9 ± 29.315.7 ± 26.36
SecondaryTime to Deterioration in QoL Reflux Domain Score in the Overall Study Population

Time calculated from randomisation till worsening of reflux domain score based on European Organisation for Research and Treatment of Cancer (EORTC) questionnaire data

Time frame:
Questionnaire data collected at Baseline ie on or before date of randomisation, every 4 weeks post baseline, assessed maximum up to 27 months
Reported as:
Median · months
Time to Deterioration in QoL Reflux Domain Score in the Overall Study Population
monthsOlaparib+PaclitaxelPlacebo+Paclitaxel
Time to Deterioration in QoL Reflux Domain Score in the Overall Study Population4.3 ± 29.312.8 ± 26.36
SecondaryTime to Deterioration in QoL Anxiety Domain Score in the Overall Study Population

Time calculated from randomisation till worsening of anxiety domain score based on European Organisation for Research and Treatment of Cancer (EORTC) questionnaire data

Time frame:
Questionnaire data collected at Baseline ie on or before date of randomisation, every 4 weeks post baseline, assessed maximum up to 27 months
Reported as:
Median · months
Time to Deterioration in QoL Anxiety Domain Score in the Overall Study Population
monthsOlaparib+PaclitaxelPlacebo+Paclitaxel
Time to Deterioration in QoL Anxiety Domain Score in the Overall Study Population2.8 ± 29.311.9 ± 26.36

Adverse events

Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
OLAPARIB 100MG BD + PACLITAXEL / OLAPARIB 200MG BD—17/61 (27.9%)61/61 (100%)
PLACEBO 100MG BD + PACLITAXEL / PLACEBO 200MG BD—23/62 (37.1%)62/62 (100%)
Most frequent serious events
Showing 10 of 39
Most frequent serious events
EventOLAPARIB 100MG BD + PACLITAXEL / OLAPARIB 200MG BDPLACEBO 100MG BD + PACLITAXEL / PLACEBO 200MG BD
PNEUMONIAInfections and infestations3/616/62
FATIGUEGeneral disorders2/612/62
ASTHENIAGeneral disorders1/612/62
PAINGeneral disorders0/612/62
PYREXIAGeneral disorders1/612/62
ENTEROCOLITIS INFECTIOUSInfections and infestations0/612/62
DECREASED APPETITEMetabolism and nutrition disorders1/612/62
FEBRILE NEUTROPENIABlood and lymphatic system disorders1/610/62
NEUTROPENIABlood and lymphatic system disorders1/611/62
ACUTE MYOCARDIAL INFARCTIONCardiac disorders1/610/62
Most frequent other events
Showing 10 of 167
Most frequent other events
EventOLAPARIB 100MG BD + PACLITAXEL / OLAPARIB 200MG BDPLACEBO 100MG BD + PACLITAXEL / PLACEBO 200MG BD
NEUTROPENIABlood and lymphatic system disorders46/6140/62
ALOPECIASkin and subcutaneous tissue disorders30/6129/62
NAUSEAGastrointestinal disorders21/6126/62
DECREASED APPETITEMetabolism and nutrition disorders23/6125/62
NEUROPATHY PERIPHERALNervous system disorders22/6113/62
MYALGIAMusculoskeletal and connective tissue disorders10/6122/62
DIARRHOEAGastrointestinal disorders20/6117/62
ASTHENIAGeneral disorders19/6115/62
FATIGUEGeneral disorders15/6119/62
ABDOMINAL PAINGastrointestinal disorders15/6116/62

Baseline characteristics

Age, Continuous
Age, Continuous(years)Olaparib+PaclitaxelPlacebo+PaclitaxelTotal
Mean59.0 ± 11.6159.4 ± 11.9859.2 ± 11.75
Age, Customized
Age, Customized(Participants)Olaparib+PaclitaxelPlacebo+PaclitaxelTotal
< 50 years131023
>=50 to <65 years223052
>= 65 years272249
Sex: Female, Male
Sex: Female, Male(Participants)Olaparib+PaclitaxelPlacebo+PaclitaxelTotal
Female131831
Male494493
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Olaparib+PaclitaxelPlacebo+PaclitaxelTotal
Asian6262124
Other000
ATM status
ATM status(Participants)Olaparib+PaclitaxelPlacebo+PaclitaxelTotal
Negative313263
Positive313061
08

Study locations

7 sites
  • Research Site
    Goyang-si, 410-769, Korea, Republic of
  • Research Site
    Jeonnam, 519-763, Korea, Republic of
  • Research Site
    Seoul, 03722, Korea, Republic of
  • Research Site
    Seoul, 110-744, Korea, Republic of
  • Research Site
    Seoul, 134-791, Korea, Republic of
  • Research Site
    Seoul, 137-701, Korea, Republic of
  • Research Site
    Taegu, 705-035, Korea, Republic of
09

References and documents

Individual participant data

Plan to share: Yes — Qualified researchers can request access to anonymized individual patient-level data from AstraZeneca group of companies sponsored clinical trials via the request portal. All request will be evaluated as per the AZ disclosure commitment: https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure. Yes, indicates that AZ are accepting requests for IPD, but this does not mean all requests will be shared.

Supporting information: Study protocol, Statistical analysis plan

Time frame: AstraZeneca will meet or exceed data availability as per the commitments made to the EFPIA Pharma Data Sharing Principles. For details of our timelines, please rerefer to our disclosure commitment at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.

Access criteria: When a request has been approved AstraZeneca will provide access to the deidentified individual patient-level data in an approved sponsored tool . Signed Data Sharing Agreement (non-negotiable contract for data accessors) must be in place before accessing requested information. Additionally, all users will need to accept the terms and conditions of the SAS MSE to gain access. For additional details, please review the Disclosure Statements at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.

Data sharing details ↗ · astrazenecagroup-dt.pharmacm.com

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Feb 2010 to primary completion in May 2012, 27 months.

Results were first posted in Apr 2015, 2 years 11 months after primary completion. A results delay was requested in Jul 2013.

Of 65 industry-sponsored phase 2 interventional studies under Stomach Neoplasms, half reached primary completion within 38 months of starting (the median), counting those still running; a quarter within 25 and three quarters within 68. This study's 27 months is below that.

Counting every sponsor, half of 360 studies reached it within 50 months; a quarter within 31 and three quarters within 75.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 4, 2010
First posted
Feb 5, 2010
StartActual
Feb 2, 2010
Primary completionActual
May 11, 2012
CompletionActual
Jun 29, 2023
Results delay requested
Jul 12, 2013
Results first posted
Apr 30, 2015
Last update
Jul 20, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 20, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01063517
Lead sponsor
AstraZeneca
Responsible party
Sponsor
First posted
Feb 5, 2010
Start date
Feb 2, 2010
Primary completion
May 11, 2012
Completion
Jun 29, 2023
Results posted
Apr 30, 2015
Last update
Jul 20, 2023

Study contacts

Jane Robertson, BSc, MBCHB, MD
study director · AstraZeneca
Yung-Jue Bang, MD
principal investigator · Seoul National University Hospital

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Olaparib

Start the discussion